NCT04715529View on ClinicalTrials.gov

Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

FZJ-003

Subjects will receive FZJ-003 oral capsules in a dose escalation format.

DRUG

Placebo

Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .

Trial Locations (1)

130000

the First Bethune Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY

NCT04715529 - Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers | Biotech Hunter | Biotech Hunter